Life Sciences Tools and Services
Company Overview of Oxford Gene Technology IP Limited
Oxford Gene Technology IP Limited provides genetics research and biomarker solutions to clinical and academic research institutions worldwide. Its products include Cytocell fluorescence in situ hybridisation probes for the detection of gene rearrangements related to inherited genetic disease and cancer; ovarian cancer, myeloid, and solid tumor panels; microarray and next generation sequencing library preparation kits; constitutional v3 and constitutional v3+LOH, medical research exome, autism research, NMD research, cardiomyopathy research, eye disease research, disease-focused research, and embryo screen arrays; and CytoSure international standards for cytogenomic arrays. It offers solution...
Begbroke Science Park
Begbroke, OX5 1PF
Founded in 1995
Key Executives for Oxford Gene Technology IP Limited
Chief Executive Officer and Director
Founder, Chief Science Advisor and Director
Chief Financial Officer and Director
Executive Vice President of Group Operations and Cambridge Site Director
Executive Vice President of R&D
Compensation as of Fiscal Year 2016.
Oxford Gene Technology IP Limited Key Developments
Oxford Gene Technology Launches Two New CE-IVD Labelled Fluorescence in Situ Hybridisation Probes for Expanding Lung Cancer Portfolio
Sep 13 16
Oxford Gene Technology has launched two new CE-IVD labelled fluorescence in situ hybridisation (FISH) probes, further expanding its extensive lung cancer portfolio. The Cytocell Aquarius ROS1 Plus Breakapart and RET Breakapart probes specifically and accurately detect rearrangements in the genome associated with the most common form of lung cancer non-small cell lung cancer (NSCLC). The new additions complement OGT’s existing NSCLC probe range (including ALK Breakapart, EGFR Amplification and EML Breakapart), providing a comprehensive solution for diagnosis and patient stratification. The probes are available in two economical sizes and are premixed in hybridisation buffer — saving time and minimising potential errors. Fully optimised for use on formalin-fixed, paraffin-embedded (FFPE) samples, Cytocell FISH probes deliver high-intensity signals with minimal background for accurate, reliable results and confident diagnoses.
Oxford Gene Technology Launches 9 New Cytocell Aquarius® FISH Probes
Jun 21 16
Oxford Gene Technology has further expanded its extensive catalogue of fluorescence in situ hybridisation (FISH) products with 9 new Cytocell Aquarius ® probes. The range now includes ETV6 Proximal Probe Green, ETV6 Distal Probe Red, MPO Probe Red, TP53 Probe Green, NUP214 Probe Red, DEK Probe Green, TAS2R1 (5p15.31) Probe Green, Chromosome 9 Satellite III Probe Aqua and Chromosome 15 Alpha Satellite Probe Red. These cost-effective and quality-assured probes produce specific, high-intensity signals with excellent contrast and minimal background for the utmost confidence in results. Optimised for use on common sample types, the probes are also pre-mixed in hybridisation buffer, increasing ease of use and reducing errors in the laboratory. Highlighting OGT’s renowned customer service, the new additions to the range have been developed in response to high customer demand via the Cytocell myProbes ® FISH probes service. This custom probe design and manufacturing service enables OGT customers to purchase unique, fully quality-assured FISH probes for virtually any sequence in the entire human genome using the proprietary Cytocell BAC clone collection. The new additions to the Cytocell Aquarius ® probe range are currently only available within North America as analyte specific reagents (ASRs), analytical and performance characteristics are not established. CE-marked IVD versions for sale in Europe are anticipated.
Oxford Gene Technology Reports Revenue Results for the Fiscal 2015
Dec 10 15
Oxford Gene Technology reported revenue results for the fiscal 2015. Total revenue grew by 12% to £17.1 million despite divestments and anticipated fall in royalty income.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|